PAC4 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of PAC4, also known as proteasome activator complex subunit 4. PAC4 is part of the regulatory components of the proteasome, a multi-subunit complex responsible for the degradation of unwanted or misfolded proteins within the cell. The proteasome plays a crucial role in maintaining protein homeostasis by regulating protein turnover through a process known as ubiquitin-dependent proteolysis. PAC4, as part of the proteasome activator complex, is involved in the assembly or activation of the proteasome, ensuring its proper function in protein degradation. By inhibiting PAC4, researchers can disrupt the regulation of the proteasome, providing a way to study the specific roles that PAC4 and its associated complexes play in proteasome function and protein degradation.
In research settings, PAC4 inhibitors are valuable tools for investigating the molecular mechanisms governing protein degradation and the regulation of proteasome activity. Inhibiting PAC4 allows scientists to explore how disruption of the proteasome's regulatory machinery affects the breakdown of proteins, leading to potential accumulation of damaged or misfolded proteins within the cell. This inhibition provides insight into the interactions between PAC4 and other proteasomal subunits, as well as how these interactions influence the assembly and efficiency of the proteasome. Furthermore, PAC4 inhibitors can help researchers understand the broader regulatory networks that involve the proteasome in cellular processes such as cell cycle progression, stress response, and metabolic regulation. Through these studies, PAC4 inhibitors enhance our understanding of proteasome regulation and the essential role that PAC4 plays in maintaining cellular proteostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which blocks cAMP degradation, thereby potentiating the action of cAMP-dependent pathways that activate PAC4. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC phosphorylation can lead to the activation of downstream proteins, potentially enhancing PAC4 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits various protein kinases, which may decrease regulatory phosphorylation on inhibitory sites of proteins in the same pathway as PAC4, leading to its activation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P binds to its G-protein-coupled receptors, initiating signaling cascades that can lead to the activation of PAC4 through intracellular calcium mobilization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that alters the PI3K/AKT pathway. By inhibiting this pathway, LY294002 can lead to compensatory activation of pathways that enhance PAC4 activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that facilitates the influx of calcium, increasing intracellular calcium and activating calcium-dependent signaling that can enhance PAC4 activity. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
db-cAMP is a cAMP analog that is resistant to degradation by phosphodiesterases, enhancing cAMP-dependent signaling and potentially leading to the activation of PAC4. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that may non-selectively activate PAC4 by inhibiting kinases that negatively regulate PAC4's activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate the MAPK pathway through stress response mechanisms, potentially enhancing the activity of PAC4. | ||||||